



# Cellular responses to calcium oxalate



Nephrolithiasis is caused by the  
**formation** and **retention**  
of crystals in the kidney


**crystal formation**  
is physiologic  
**crystal retention**  
is pathologic






# Oxalosis & Hyperoxaluria

November 20-21, 2003




**Oxalosis &  
Hyperoxaluria**

November 20-21, 2003




**Oxalosis &  
Hyperoxaluria**

November 20-21, 2003



**Oxalosis &  
Hyperoxaluria**

November 20-21, 2003




# Crystal binding


phalloidin-FITC

calcium oxalate crystals

*light reflection confocal laser scanning microscopy*



subconfluence



confluence









# Hyaluronan staining


subconfluent

subconfluent +  
hyaluonidase

confluent









# Effect hyaluronidase



# Development of polarized monolayers


Hyaluronan

Hyaluronan receptor, CD44






mus MC  
Zafar

# Mechanical damage




## Crystal binding during wound healing




# Hyaluronan staining

days post-injury


0











1





2




4



# Pericellular matrices



control



*streptomyces*  
hyaluronidase

## Primary cultures of human renal tubular cells

Verhulst A, Persy VP, Van Rompay AR, Verstrepen WA, Helbert MF, De Broe ME.  
*J Am Soc Nephrol* 13:1210-1218, 2002

Osteopontin synthesis and localization along the human nephron.




Verhulst A, Asselman M, Persy V, Schepers M, Helbert MF, Verkoelen CF, De Broe ME.  
*J Am Soc Nephrol* 14:107-115, 2003

Crystal retention capacity of cells in the human nephron: involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal binding-into a nonadherent epithelium.





## Osteopontin and CD44




subconfluence

confluence


# Treatment



# Effect indomethacin on PGE2 synthesis during wound healing



# Effect indomethacin on hyaluronan synthesis during wound healing







# Effect indomethacin on hyaluronan expression during wound healing



Undamaged control




Wound healing




Wound healing  
+25  $\mu$ M indomethacin



# Effect indomethacin on crystal binding during wound healing




Wound healing




Wound healing + indomethacin




## Effect meloxicam (COX-2-specific NSAID)



PGE<sub>2</sub>




hyaluronan




COM crystal binding

# Rat studies








# Ethylene glycol (EG)




# Effect ethylene glycol on urinary oxalate and calcium excretion






## crystalluria after 24 h ethylene glycol



untreated control




ethylene glycol (0.5%)



# Crystal retention in the renal tubules




Total number of intratubular crystals



# Ethylene glycol-induced renal tubular damage




Day 1




Normal  
morphology

Day 4 - 8




Brush  
border loss

Day 4 - 8




Dilatation


Day 4 - 8





PCNA  
Regeneration

Day 4 - 8









# Crystals are selectively retained in damaged tubules



# Crystals predominantly bind to regenerating cells






## Hyaluronan expression in the normal kidney




cortex




medulla





# Ethylene glycol-induced up-regulated expression of hyaluronan (OPN and CD44)



**Oxalosis &  
Hyperoxaluria**

November 20-21, 2003




hyaluronan

Oxalosis &  
Hyperoxaluria

November 20-21, 2003



osteopontin



Oxalosis &  
Hyperoxaluria

November 20-21, 2003



CD44


# Human studies




# acute renal failure/tubular necrosis



hyaluronan






von kossa



# Transplanted kidney in patient with primary hyperoxaluria type I



hyaluronan





# Mechanisms leading to crystal retention


• Metabolic


• Environmental

• Pathologic

• Mechanical

} Stress





hyaluronan binding proteins

hyaluronidases

hyaluronan

hyaluronan receptors

hyaluronan synthases

# Conclusion

**Recurrent renal stone formation  
is an inflammation-mediated  
disease**



**Erasmus MC**

University Medical Center Rotterdam



*Department of Urology  
Erasmus MC, Rotterdam  
The Netherlands*

*Marino Asselman*

*Eddy van Ballegooijen*

*Chris Bangma*

*Marieke Schepers*

*Paul Verhagen*

*Carl Verkoelen*



**University  
of Antwerp**

*Department of Nephrology  
University of Antwerp  
Belgium*

*Mark Helbert*

*Patric D'Haese*

*Marc De Broe*

*Veerle Persy*

*Benjamin Vervaet*

*Anja Verhulst*

**SUWO**

Stichting Urologisch  
Wetenschappelijk Onderzoek



Oxalosis and  
Hyperoxaluria  
Foundation



Dutch Kidney  
Foundation

Erasmus MC



# Ethylene glycol (EG)



anti-freeze

*alcohol  
dehydrogenase*

glycoaldehyde

*aldehyde oxidase*

glycolate

*LDH or glycolate oxidase  
(GO)*

*glycolate reductase (GR)*

glyoxylate

*alanine:glyoxylate  
aminotransferase (AGT)*


*LDH or glycolate oxidase (GO)*

glycine

oxalate



# Primary Hyperoxaluria type 1



# Primary hyperoxaluria type 1

metabolic

membrane phospholipids

*Phospholipase A<sub>2</sub> (PLA<sub>2</sub>)*

arachidonic acid

*Cyclooxygenases (COX-1, COX-2)*

prostaglandins

*Hyaluronan synthases (HAS-1, HAS-2, ...)*

hyaluronan

crystal retention

nephrocalcinosis/nephrolithiasis

tubular obstruction

loss of renal function

hyperoxalemia

oxalosis

fish-oil

NSAIDs

Inhibitors

glycine

Endoplasmic reticulum (ER) stress

mitogen-activated protein kinase (MAPK)

Erasmus MC

